Status and phase
Conditions
Treatments
About
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural killer/T cell lymphoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
47 participants in 1 patient group
Loading...
Central trial contact
Qingqing Cai, MD. PhD.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal